Cartesian Therapeutics Inc. (RNAC) — Cash Flow Reinvestment Rate
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Reinvestment Rate of 0.91x as of September 2024, reinvesting $12.40 Million (capex $6.20 Million plus investments $-6.20 Million) from operating cash flow of $13.69 Million. Check Cartesian Therapeutics Inc. (RNAC) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cartesian Therapeutics Inc. Cash Flow Reinvestment Rate (2020–2020)
Historical reinvestment intensity for Cartesian Therapeutics Inc. across 1 annual periods. Explore Cartesian Therapeutics Inc. (RNAC) investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Cartesian Therapeutics Inc. (2020–2020)
Year-by-year capital reinvestment analysis for Cartesian Therapeutics Inc.. For live market cap and broader valuation context, see RNAC market cap.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 0.04x | $1.56 Million | $34.88 Million | $815.00K | — |